Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis

Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ordaya, Eloy E, Beam, Elena, Yao, Joseph D, Razonable, Raymund R, Vergidis, Paschalis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214166/
https://www.ncbi.nlm.nih.gov/pubmed/35859990
http://dx.doi.org/10.1093/ofid/ofac283
_version_ 1784730951952105472
author Ordaya, Eloy E
Beam, Elena
Yao, Joseph D
Razonable, Raymund R
Vergidis, Paschalis
author_facet Ordaya, Eloy E
Beam, Elena
Yao, Joseph D
Razonable, Raymund R
Vergidis, Paschalis
author_sort Ordaya, Eloy E
collection PubMed
description Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
format Online
Article
Text
id pubmed-9214166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-92141662022-06-22 Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis Ordaya, Eloy E Beam, Elena Yao, Joseph D Razonable, Raymund R Vergidis, Paschalis Open Forum Infect Dis Brief Report Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission. Oxford University Press 2022-06-07 /pmc/articles/PMC9214166/ /pubmed/35859990 http://dx.doi.org/10.1093/ofid/ofac283 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Ordaya, Eloy E
Beam, Elena
Yao, Joseph D
Razonable, Raymund R
Vergidis, Paschalis
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title_full Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title_fullStr Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title_full_unstemmed Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title_short Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
title_sort characterization of early-onset severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients who received tixagevimab-cilgavimab prophylaxis
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214166/
https://www.ncbi.nlm.nih.gov/pubmed/35859990
http://dx.doi.org/10.1093/ofid/ofac283
work_keys_str_mv AT ordayaeloye characterizationofearlyonsetsevereacuterespiratorysyndromecoronavirus2infectioninimmunocompromisedpatientswhoreceivedtixagevimabcilgavimabprophylaxis
AT beamelena characterizationofearlyonsetsevereacuterespiratorysyndromecoronavirus2infectioninimmunocompromisedpatientswhoreceivedtixagevimabcilgavimabprophylaxis
AT yaojosephd characterizationofearlyonsetsevereacuterespiratorysyndromecoronavirus2infectioninimmunocompromisedpatientswhoreceivedtixagevimabcilgavimabprophylaxis
AT razonableraymundr characterizationofearlyonsetsevereacuterespiratorysyndromecoronavirus2infectioninimmunocompromisedpatientswhoreceivedtixagevimabcilgavimabprophylaxis
AT vergidispaschalis characterizationofearlyonsetsevereacuterespiratorysyndromecoronavirus2infectioninimmunocompromisedpatientswhoreceivedtixagevimabcilgavimabprophylaxis

Ejemplares similares